BioCentury
ARTICLE | Company News

Bicycle, AZ in bicyclic peptide deal

December 2, 2016 12:30 AM UTC

Bicycle Therapeutics Ltd. (Cambridge, U.K.) and AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered to identify and develop bicyclic peptides to treat respiratory, cardiovascular and metabolic diseases. Bicyclic peptides are small molecules designed to show affinity and target specificity similar to antibodies.

The deal covers an undisclosed number of targets specified by AstraZeneca. If all the programs reach the market, Bicycle would receive more than $1 billion, including an undisclosed upfront payment, R&D funding and milestones, plus royalties...